MedTrace Logo

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

NCT07010159 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-05-19

No results posted yet for this study

Summary

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Conditions

  • Pericarditis
  • Pericarditis Acute
  • Recurrent Pericarditis

Interventions

DRUG

KPL-387

administered by subcutaneous injection

DRUG

Placebo

administered by subcutaneous injection

Sponsors & Collaborators

  • Kiniksa Pharmaceuticals, GmbH

    collaborator INDUSTRY

  • Kiniksa Pharmaceuticals International, plc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2027-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Greece
  • Italy
  • Poland
  • Serbia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07010159 on ClinicalTrials.gov